000304972 001__ 304972
000304972 005__ 20251219141339.0
000304972 0247_ $$2doi$$a10.1053/j.semnuclmed.2025.09.003
000304972 0247_ $$2pmid$$apmid:41015659
000304972 0247_ $$2ISSN$$a0001-2998
000304972 0247_ $$2ISSN$$a1558-4623
000304972 037__ $$aDKFZ-2025-01963
000304972 041__ $$aEnglish
000304972 082__ $$a610
000304972 1001_ $$aKabunda, Joseph$$b0
000304972 245__ $$aNectin-4, Bladder Cancer, and Nuclear Medicine: A Theranostic Frontier.
000304972 260__ $$aNew York, NY [u.a.]$$bElsevier$$c2025
000304972 3367_ $$2DRIVER$$aarticle
000304972 3367_ $$2DataCite$$aOutput Types/Journal article
000304972 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1766149870_2932235$$xReview Article
000304972 3367_ $$2BibTeX$$aARTICLE
000304972 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000304972 3367_ $$00$$2EndNote$$aJournal Article
000304972 500__ $$aVolume 55, Issue 6, November 2025, Pages 912-927
000304972 520__ $$aBladder cancer is among the top ten most common cancers globally, with advanced or metastatic disease associated with dismal survival outcomes. Current diagnostic imaging and therapies have significant limitations, highlighting the urgent need for novel theranostic targets. Nectin-4, a cell adhesion molecule frequently overexpressed in bladder cancer, especially urothelial carcinoma (∼60%-87% of tumors), has emerged as a promising biomarker and therapeutic target. This review critically evaluates the role of Nectin-4 in bladder cancer and explores its exciting potential in nuclear medicine for combined molecular imaging and targeted radionuclide therapy-embracing the 'theranostic' paradigm. Nectin-4 is abundantly and selectively expressed in most urothelial carcinomas, correlating with advanced disease and poorer prognosis. Clinically validated by the FDA-approved antibody-drug conjugate enfortumab vedotin, Nectin-4 targeting achieves objective response rates around 40%-50% and significantly improves survival in refractory advanced urothelial carcinoma. Recent clinical advances in Nectin-4-targeted PET imaging (such as 68Ga-labeled agents) have demonstrated excellent tumor localization and specificity, enabling precise patient selection for targeted therapies. Additionally, emerging radionuclide therapeutics (eg, 225Ac- and 177Lu-based agents) show promising preclinical and early clinical efficacy, robust tumor targeting, and favorable safety profiles. Targeting Nectin-4 represents a new frontier in the management of bladder cancer, bridging the gap between precise molecular diagnostics and personalized targeted radionuclide therapy. Ongoing clinical trials and translational research are rapidly advancing this promising theranostic strategy towards routine clinical application, with significant potential to enhance patient selection, treatment monitoring, and ultimately, clinical outcomes.
000304972 536__ $$0G:(DE-HGF)POF4-899$$a899 - ohne Topic (POF4-899)$$cPOF4-899$$fPOF IV$$x0
000304972 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000304972 7001_ $$aNdlovu, Honest$$b1
000304972 7001_ $$aSingh, Karishma$$b2
000304972 7001_ $$aSibiya, Sandile$$b3
000304972 7001_ $$aMdanda, Sipho$$b4
000304972 7001_ $$aRamonaheng, Kamo$$b5
000304972 7001_ $$aAl-Ibraheem, Akram$$b6
000304972 7001_ $$0P:(DE-HGF)0$$aHerrmann, Ken$$b7
000304972 7001_ $$aMokoala, Kgomotso$$b8
000304972 7001_ $$aSathekge, Mike$$b9
000304972 773__ $$0PERI:(DE-600)2133379-8$$a10.1053/j.semnuclmed.2025.09.003$$gp. S0001299825001187$$n6$$p912-927$$tSeminars in nuclear medicine$$v55$$x0001-2998$$y2025
000304972 909CO $$ooai:inrepo02.dkfz.de:304972$$pVDB
000304972 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000304972 9131_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000304972 9141_ $$y2025
000304972 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2024-12-27$$wger
000304972 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-27
000304972 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-27
000304972 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-27
000304972 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-27
000304972 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-27
000304972 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-27
000304972 915__ $$0StatID:(DE-HGF)1120$$2StatID$$aDBCoverage$$bBIOSIS Reviews Reports And Meetings$$d2024-12-27
000304972 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-27
000304972 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-27
000304972 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bSEMIN NUCL MED : 2022$$d2024-12-27
000304972 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2024-12-27
000304972 9201_ $$0I:(DE-He78)ED01-20160331$$kED01$$lDKTK Koordinierungsstelle Essen/Düsseldorf$$x0
000304972 980__ $$ajournal
000304972 980__ $$aVDB
000304972 980__ $$aI:(DE-He78)ED01-20160331
000304972 980__ $$aUNRESTRICTED